Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst (Nasdaq: BCRX) reported preliminary, unaudited ORLADEYO net revenue of $601 million for full year 2025, up 37% y-o-y and above prior guidance of $590M–$600M. Excluding European ORLADEYO, 2025 net revenue was $563 million (+43% comparable). Q4 2025 ORLADEYO revenue was $151 million (+22% y-o-y; +36% comparable). The company projects 2026 ORLADEYO revenue $625M–$645M, total revenue $635M–$660M, and non-GAAP operating expenses $380M–$390M (or $450M–$470M including the expected Astria acquisition). Cash and investments totaled $338 million at December 31, 2025.
BioCryst (Nasdaq: BCRX) announced that its compensation committee granted a newly hired employee 18,300 restricted stock units (RSUs) as inducement equity under Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted effective January 2, 2026, vest in four equal annual installments beginning on the one-year anniversary of the grant date, and are subject to the recipient’s continued service and the terms of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement.
BioCryst (Nasdaq: BCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. ET.
A live audio webcast and replay will be available in the Investors & Media section of BioCryst’s website at www.biocryst.com.
BioCryst (NASDAQ:BCRX) announced FDA approval (Dec 12, 2025) of ORLADEYO oral pellets (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in patients aged 2 to <12 years. ORLADEYO becomes the first and only targeted oral prophylactic therapy for HAE patients aged 2 and older. Approval was supported by interim data from the APeX-P pediatric trial showing ORLADEYO was well tolerated and produced early, sustained reductions in monthly attack rates; the most common TEAE was nasopharyngitis. The pellet formulation is sprinkle-like for easy administration. Regulatory filings are underway in Europe, Japan, and other territories.
BioCryst (Nasdaq: BCRX) announced that its compensation committee granted inducement equity to four newly hired employees effective Dec 1, 2025. The grants consist of stock options to purchase an aggregate of 57,100 shares and restricted stock units covering 46,400 shares, totaling 103,500 shares.
The options have an exercise price of $7.13 per share, equal to the closing price on the grant date, a 10-year term, and the options and RSUs vest in four equal annual installments beginning on the one-year anniversary, subject to continued service. Grants were made under BioCryst’s Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst (Nasdaq: BCRX) announced early termination of the Hart-Scott-Rodino (HSR) waiting period for its proposed acquisition of Astria Therapeutics.
Termination of the HSR waiting period satisfies one regulatory condition for the Merger. BioCryst expects the Merger to close in Q1 2026, subject to other customary closing conditions.
Astria Therapeutics (NASDAQ: ATXS) reported Q3 2025 results and provided a corporate update on November 12, 2025. Key corporate items include a definitive agreement for BioCryst to acquire Astria for $8.55 cash plus 0.59 BCRX shares per Astria share, with closing expected in Q1 2026 pending stockholder approval. Clinical highlights: final ALPHA-STAR data in 29 HAE patients showed a 84–92% mean and 93–100% median reduction in attack rate through six months; ALPHA-ORBIT Phase 3 topline results expected in early 2027. Financials: cash of $227.7M at 9/30/25, runway into 2028 assuming standalone operations; Q3 net loss $31.6M (-$0.55/share).
BioCryst (Nasdaq: BCRX) reported APeX-P second interim data and psychosocial findings at ACAAI on Nov 6, 2025. An oral granule formulation of ORLADEYO (berotralstat) for ages 2 to <12 is under FDA review with a target action date of Dec 12, 2025. In 29 pediatric participants (mean exposure 63.9 weeks), ORLADEYO produced early and sustained reductions in attacks: 65.5% attack-free at month 1, 70.4% attack-free at month 12, and a median monthly attack rate of 0 for 11 of 12 months. Continuation was high (93.1% completed ≥48 weeks). Safety findings reported no new signals; most common TEAE was nasopharyngitis. Separate posters documented early-onset HAE (median diagnosis age 2.0) and frequent, stressful ED/hospital visits for children and caregivers.
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units covering an aggregate of 30,700 shares to three newly hired employees, effective November 3, 2025.
The awards were approved by the compensation committee as inducements under Nasdaq Listing Rule 5635(c)(4) and are governed by the company’s Inducement Equity Incentive Plan and individual RSU agreements. The RSUs vest in four equal annual installments beginning on the one‑year anniversary of the grant, each installment subject to the employee’s continued service.
BioCryst (Nasdaq:BCRX) will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 12:00 p.m. ET.
The event will be available via a live audio webcast with a replay. Investors can access the live audio and replay in the Investors & Media section at www.biocryst.com.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
